Abstract: The present invention is concerned with a novel circulating biomarker of cardiac disease. The present invention provides assays, methods and test kits for detection of insulin-like growth factor binding protein 3 and to the utility of IGFBP-3 in clinically relevant diagnoses of acute coronary syndromes including, for example, unstable angina pectoris, alongside classical risk factors including history of angina and abnormal electrocardiogram. The present invention further provides assays, methods and test kits for identifying inducible cardiac ischaemia in a patient by measuring the levels of IGFBP-3 in conjunction with other risk factors such as an elevated levels of troponin, an abnormal electrocardiogram, a history of heart failure and/or a history of myocardial alongside interrogation of the IGFBP-3 or ?IGFBP-3 levels in a sample obtained from the patient, and using this information to inform prophylactic or therapeutic treatment options for ischaemia.

Abstract: Disclosed is an aerosol-delivery component for an aerosol-generating system (e.g., a smoking substitute system), said component comprising a tank for storing an aerosol precursor and a vaporization chamber housing a vaporizer. The tank being is in fluid communication with the vaporizer. The component further comprises a channel extending from the vaporization chamber to the tank defining an unimpeded air flow pathway from the vaporization chamber into the tank.

Abstract: Diagnostics relating to C-type natriuretic and erythropoietin signal peptides and fragments, and kits, uses and applications therefore.

Abstract: The present invention relates to the diagnosis of unstable angina in a patient. In addition, the present invention relates to predicting the complication of stroke and/or heart failure in a patient as a consequence of developing unstable angina.

Abstract: Ghrelin signal peptide fragment assays and kits useful in the diagnosis, prognosis, risk stratification, assessing, staging, monitoring, categorizing and determination of further diagnoses and treatment regimens in subjects with various disorders, diseases and conditions including, pneumonia, heart failure, or pneumonia and heart failure or suspected pneumonia, heart failure, or pneumonia and heart failure, and methods for monitoring treatment.

Abstract: The invention provides binding agents and assays tor insulin signal peptide. The agents and assays are useful in methods tor predicting, diagnosing, assessing or monitoring acute cardiac disorders, glucose handling disorders and diabetes in a subject. Also provided are nucleotides, polypeptides, and kits useful in the methods of the invention.

Abstract: Diagnostics relating to C-type natriuretic and erythropoietin signal peptides and fragments, and kits, uses and applications therefore.

Abstract: The present invention relates generally to assays, methods and kits for the prognosis and/or diagnosis of cardiac disorders. The present invention also provides, for example, binding agents to a novel class of circulating troponin biomarkers for use in predicting or diagnosing a cardiac disorder other than myocardial infarction or unstable angina. In addition, the binding agents of the present invention may be used to enhance the sensitivity and false positive performance of cardiac troponins in the prognosis and diagnosis of myocardial infarction.

Abstract: Compounds and compositions comprising a B-type natriuretic signal peptide fragment agent, and methods of use thereof, are provided for the treatment or prevention of cardiovascular diseases, disorders, and conditions.

Abstract: The invention provides binding agents and assays tor insulin signal peptide. The agents and assays are useful in methods tor predicting, diagnosing, assessing or monitoring acute cardiac disorders, glucose handling disorders and diabetes in a subject. Also provided are nucleotides, polypeptides, and kits useful in the methods of the invention.

Abstract: Compounds and compositions comprising a B-type natriuretic signal peptide fragment agent, and methods of use thereof, are provided for the treatment or prevention of cardiovascular diseases, disorders, and conditions.

Abstract: The present invention relates generally to assays, methods and kits for the prognosis and/or diagnosis of cardiac disorders. The present invention also provides, for example, binding agents to a novel class of circulating cardiac troponin T upstream open reading frame (TnTuORF) peptide biomarkers for use in predicting or diagnosing a cardiac disorder other than myocardial infarction or unstable angina. In addition, the binding agents of the present invention may be used to enhance the sensitivity and false positive performance of cardiac troponins in the prognosis and diagnosis of myocardial infarction.

Abstract: The invention provides binding agents and assays for insulin signal peptide. The agents and assays are useful in methods for predicting, diagnosing, assessing or monitoring acute cardiac disorders, glucose handling disorders and diabetes in a subject. Also provided are nucleotides, polypeptides, and kits useful in the methods of the invention.

Abstract: The present invention relates generally to assays, methods and kits for the prognosis and/or diagnosis of cardiac disorders. The present invention also provides, for example, binding agents to a novel class of circulating cardiac troponin T upstream open reading frame (TnTuORF) peptide biomarkers for use in predicting or diagnosing a cardiac disorder other than myocardial infarction or unstable angina. In addition, the binding agents of the present invention may be used to enhance the sensitivity and false positive performance of cardiac troponins in the prognosis and diagnosis of myocardial infarction.

Abstract: The invention provides methods for predicting, diagnosing or monitoring acute cardiac disorders, cardiac transplant rejection, or distinguishing acute cardiac disorders from pulmonary disorders, by measuring BNP signal peptide levels in a sample taken from a subject shortly after onset of, or presentation with the disorder or transplant rejection.

Abstract: The invention provides methods for predicting, diagnosing or monitoring acute cardiac disorders, cardiac transplant rejection, or distinguishing acute cardiac disorders from pulmonary disorders, by measuring BNP signal peptide levels in a sample taken from a subject shortly after onset of, or presentation with the disorder or transplant rejection.

Abstract: Diagnostics relating to C-type natriuretic and erythropoietin signal peptides and fragments, and kits, uses and applications therefor.

Abstract: The invention provides methods for predicting, diagnosing or monitoring acute cardiac disorders, cardiac transplant rejection, or distinguishing acute cardiac disorders from pulmonary disorders, by measuring BNP signal peptide levels in a sample taken from a subject shortly after onset of, or presentation with the disorder or transplant rejection.

Abstract: Ghrelin signal peptide fragment assays and kits useful in the diagnosis, prognosis, risk stratification, assessing, staging, monitoring, categorizing and determination of further diagnoses and treatment regimens in subjects with various disorders, diseases and conditions including, pneumonia, heart failure, or pneumonia and heart failure or suspected pneumonia, heart failure, or pneumonia and heart failure, and methods for monitoring treatment.

Abstract: The invention provides binding agents and assays for ghrelin signal peptide. The agents and assays are useful in methods for predicting, diagnosing, assessing or monitoring acute cardiac disorders, glucose handling disorders and diabetes in a subject. Also provided are nucleotides, polypeptides, and kits useful in the methods of the invention.